| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $710K | -65.6% |
| SG&A Expense | $1.0M | -50.1% |
| Operating Income | -$1.9M | +60.5% |
| Pre-tax Income | $1.9M | -61.3% |
| Net Income | -$1.9M | +61.3% |
| EPS (Basic) | -$0.03 | +57.1% |
| EPS (Diluted) | -$0.03 | +57.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $129K | -83.2% |
| Accounts Receivable | $76K | -6.2% |
| Current Assets | $205K | -75.8% |
| Total Assets | $251K | -74.9% |
| Current Liabilities | $545K | +15.2% |
| Total Liabilities | $545K | -14.0% |
| Stockholders' Equity | -$294K | -180.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$1.4M | +57.1% |
| Capital Expenditures | $2K | +0.0% |
| Investing Cash Flow | -$2K | +0.0% |
| Financing Cash Flow | $750K | -25.0% |
| Free Cash Flow | -$1.4M | +57.1% |